Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022790 | 0.90 | CNR1 (0.44) | CNR1ALDH1A1CNR2HPGDKMT2A | |
| SCHEMBL5022760 | 0.82 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL5022752 | 0.78 | ACHE (0.41) | PRPS1CNR1CNR2ACHEHTR4 | |
| SCHEMBL5017992 | 0.77 | LMNA (0.44) | ALDH1A1CNR2HPGDNPSR1LMNA | |
| SCHEMBL5022381 | 0.76 | PDE4D (0.53) | — | |
| SCHEMBL5025322 | 0.76 | AR (0.40) | CNR1ALDH1A1CNR2KDM4EHPGD | |
| SCHEMBL7176265 | 0.69 | CNR1 (0.43) | CNR1ALDH1A1CNR2KDM4EKMT2A | |
| SCHEMBL5016438 | 0.68 | CCR2 (0.47) | ALDH1A1CNR2MAPT | |
| SCHEMBL5022796 | 0.68 | CNR1 (0.42) | CNR1CNR2ACHEHTR4 | |
| SCHEMBL5018088 | 0.67 | MAPT (0.47) | ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | PRPS1 4490/4885CNR1 33/4885ALDH1A1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.